Proteomic Study to Survey the CIGB-552 Antitumor Effect.
CIGB-552 is a cell-penetrating peptide that exerts in vitro and in vivo antitumor effect on cancer cells. In the present work, the mechanism involved in such anticancer activity was studied using chemical proteomics and expression-based proteomics in culture cancer cell lines. CIGB-552 interacts wit...
| Published in: | BioMed Research International Vol. 2015; pp. 1 - 19 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | pictorial research tables/charts Journal Article |
| Published: |
Wiley-Blackwell
10/20/2015
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128635454&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 128635454 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 10/20/2015 vid: 2015 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 128635454 128635454 128635454 10.1155/2015/124082 128635454 ppf: 1 ppct: 18 formats: fmt: @attributes: type: P tig: atl: Proteomic Study to Survey the CIGB-552 Antitumor Effect. aug: au: Rodríguez-Ulloa, Arielis Gil, Jeovanis Ramos, Yassel Hernández-Álvarez, Lilian Flores, Lisandra Oliva, Brizaida García, Dayana Sánchez-Puente, Aniel Musacchio-Lasa, Alexis Fernández-de-Cossio, Jorge Padrón, Gabriel López, Luis J. González Besada, Vladimir Guerra-Vallespí, Maribel affil: Department of Proteomics, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba sug: subj: Proteomics Antineoplastic Agents Peptides Pharmacodynamics Surveys Cell Line, Tumor Drug Effects Gene Expression Cell Proliferation Apoptosis NF-kappa B Drug Effects Signal Transduction Drug Effects Human Peptides Therapeutic Use Neoplasms Drug Therapy ab: CIGB-552 is a cell-penetrating peptide that exerts in vitro and in vivo antitumor effect on cancer cells. In the present work, the mechanism involved in such anticancer activity was studied using chemical proteomics and expression-based proteomics in culture cancer cell lines. CIGB-552 interacts with at least 55 proteins, as determined by chemical proteomics. A temporal differential proteomics based on iTRAQ quantification method was performed to identify CIGB-552 modulated proteins. The proteomic profile includes 72 differentially expressed proteins in response to CIGB-552 treatment. Proteins related to cell proliferation and apoptosis were identified by both approaches. In line with previous findings, proteomic data revealed that CIGB-552 triggers the inhibition of NF-κB signaling pathway. Furthermore, proteins related to cell invasion were differentially modulated by CIGB-552 treatment suggesting new potentialities of CIGB-552 as anticancer agent. Overall, the current study contributes to a better understanding of the antitumor action mechanism of CIGB-552. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|